NCT04616560 2026-03-19Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent OsteosarcomaNational Cancer Institute (NCI)Phase 2 Suspended77 enrolled
NCT06311214 2026-03-06Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)National Cancer Institute (NCI)Phase 2 Recruiting500 enrolled